Switch to
More onapp

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO
Health CarePharmaceuticals
MidcapWith a market cap of ₹22,505 cr, stock is ranked 212
Low RiskStock is 1.24x as volatile as Nifty
1,341.855.70 (+0.43%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹22,505 cr, stock is ranked 212
Low RiskStock is 1.24x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
13.28
PB RatioPB Ratio
8.45
Dividend YieldDiv. Yield
6.77%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

43%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. It manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. It offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Investor PresentationView older 

Aug 24, 2022

PDF
View Older Presentations

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Financial TrendFinancial statements 

20192020202120223.283.853.144.700.450.090.361.69
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 22, 2022

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Loss of share certificate 
Announced OnNov 18, 2022

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Loss of share certificate | Download

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Loss of share certificate | Download

Cash Dividend 
Ex. DateJul 7, 2022

Special • Div/Share: ₹ 60

See all events